USPTO serial 79273317
BELESALA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 27, 2020
- Examiner
- JAGANNATHAN, SIDDHARTH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with BELESALA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $850
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Mallinckrodt Pharmaceuticals Ireland Limited
IE
Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
Mallinckrodt Pharmaceuticals Ireland Limited
IE
Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
Mallinckrodt Pharmaceuticals Ireland Limited
IE
Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Camille M. Miller
Camille M. Miller Cozen O'Connor1650 Market Street, Suite 2800Philadelphia, PA 19103United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of neurological diseases and disorders, nephrotic diseases, endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases and disorders, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous state, gastrointestinal diseases, hepatic diseases and disorders, biliary diseases and disorders, renal disorders, cardiovascular and lipid-related diseases and disorders, inflammatory and autoimmune diseases and disorders; intravenous analgesics and antipyretics; syringes sold prefilled with pharmaceutical preparations for the treatment of neurological diseases and disorders, nephrotic diseases, endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases and disorders, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous state, gastrointestinal diseases, hepatic diseases and disorders, biliary diseases and disorders, renal disorders, cardiovascular and lipid-related diseases and disorders, inflammatory and autoimmune diseases and disorders, and intravenous analgesics and antipyretics | ACTIVE | — |
| 010 | Medical apparatus and instruments for use in connection with the administration of gases to patients for medical and therapeutic purposes and accessories and parts thereof, namely, medical and therapeutic gas delivery systems comprised primarily of gas cylinders, valves, regulators, flow meters, delivery hoses and apparatus and instruments for setting, measuring and regulating the mixture of medical and therapeutic gases delivered to patients; therapeutic medical device and accessories and parts thereof for extracting blood from the body, separating blood, treating it extracorporally, and returning it to the body used for extracorporeal photopheresis, extracorporeal photo immune therapy, extracorporeal photo chemotherapy, and cellular therapies; medical device, namely, medical syringes used for manual injection | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
- Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
- Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named BELESALA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 4, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 13, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 13, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 13, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 27, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 21, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 4, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 11, 2021 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 11, 2021 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jan 27, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 27, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 11, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 11, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 7, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 22, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 22, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 22, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 7, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 7, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 7, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 7, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 7, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 6, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 6, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 8, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 21, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 21, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 12, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 11, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 11, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 10, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 6, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 5, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |